Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short term Debt (2016 - 2025)

Northwest Biotherapeutics' Short term Debt history spans 13 years, with the latest figure at $9.4 million for Q4 2025.

  • Quarterly results put Short term Debt at $9.4 million for Q4 2025, up 324.34% from a year ago — trailing twelve months through Dec 2025 was $9.4 million (up 324.34% YoY), and the annual figure for FY2025 was $9.4 million, up 324.34%.
  • Short term Debt for Q4 2025 was $9.4 million at Northwest Biotherapeutics, down from $9.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $341.9 million in Q1 2021 to a low of $681000.0 in Q2 2025.
  • The 5-year median for Short term Debt is $9.1 million (2024), against an average of $68.9 million.
  • The sharpest move saw Short term Debt skyrocketed 4323.22% in 2021, then plummeted 98.83% in 2023.
  • Year by year, Short term Debt stood at $106.8 million in 2021, then fell by 24.56% to $80.6 million in 2022, then plummeted by 98.83% to $944000.0 in 2023, then surged by 135.06% to $2.2 million in 2024, then surged by 324.34% to $9.4 million in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $9.4 million, $9.7 million, and $681000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.